Low-Dose Naltrexone (LDN) for Depression Relapse and Recurrence
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this pilot study is to determine if taking a low dose of naltrexone in
addition to an antidepressant medication can help treat relapse or recurrence in people with
Major Depressive Disorder (MDD). The U.S. Food and Drug Administration (FDA) has approved
naltrexone for the treatment of alcohol dependence and opioid dependence, but the FDA has not
approved naltrexone to treat depression. The investigators hypothesize that patients with
breakthrough depression on an antidepressant regimen containing a pro-dopaminergic agent
assigned to treatment with low dose naltrexone will demonstrate higher rates of response
compared to those patients taking placebo.